



CLAIMS

What is claimed is:


1. An isolated, substantially enantiomerically pure compound selected from the group consisting of:






or a pharmaceutically acceptable salt thereof.


2. An enantiomeric compound represented by






or a pharmaceutically acceptable salt thereof, wherein the enantiomeric compound is present in an enantiomeric mixture having at least 90%, at least 95% or at least 99% of the enantiomeric compound.

3. A compound selected from:




4. The compound of claim 1 or 2, wherein the compound is selected from:



or a pharmaceutically acceptable salt thereof.

5. The compound of claim 3, wherein the compound is




6. A pharmaceutical composition comprising a compound of any one of claims 1-5 and a pharmaceutically acceptable excipient.

7. A method of treating depression, anxious depression, a mood disorder, an anxiety disorder, or a substance use disorder and any symptom or disorders associated therewith in a subject in need thereof, the method comprising administering to the subject in need thereof an effective amount of a compound of any one of claims 1-5.


8. A method of treating depression or anxious depression in a subject in need thereof, the method comprising administering to the subject in need thereof an effective amount of a compound of any one of claims 1-5.

9. A composition comprising an enantiomeric mixture of a compound selected from the group consisting of:




wherein the enantiomeric mixture has a significantly greater amount of the enantiomer having the lower binding affinity at the NMDA receptor MK-801 site.

10. The composition of claim 9, wherein the compound is selected from the group consisting of:




11. A composition comprising an enantiomeric mixture of a compound selected from the group consisting of:



wherein the enantiomeric mixture has a significantly greater amount of the enantiomer having the higher binding affinity at the NMDA receptor MK-801 site.


12. The composition of claim 11, wherein the compound is selected from the group consisting of:




13. A method of treating depression, anxious depression, a mood disorder, an anxiety disorder, or a substance use disorder and any symptom or disorders associated therewith in a subject in need thereof, the method comprising administering to the subject in need thereof an effective amount of a composition of any one of claims 9-12.

14. A method of treating depression or anxious depression in a subject in need thereof, the method comprising administering to the subject in need thereof an effective amount of a compound of any one of claims 9-12.


15. A method of treating depression, anxious depression, a mood disorder, an anxiety disorder, or a substance use disorder and any symptom or disorders associated therewith in a subject in need thereof, the method comprising administering to the subject in need thereof an effective amount of a composition comprising an isolated, substantially enantiomerically pure compound selected from the group consisting of:






or a pharmaceutically acceptable salt thereof.


16. A method of treating depression, anxious depression, a mood disorder, an anxiety disorder, or a substance use disorder and any symptom or disorders associated therewith in a subject in need thereof, the method comprising administering to the subject in need thereof an effective amount of a composition comprising a compound selected from the group consisting of:



17. The method of claim 15, wherein the compound is selected from the group consisting of:




18. An isolated, substantially enantiomerically pure compound represented by:




or a pharmaceutically acceptable salt thereof.

19. A method of treating depression, anxious depression, a mood disorder, an anxiety disorder, or a substance use disorder and any symptom or disorders associated therewith in a subject in need thereof, the method comprising administering to the subject in need thereof an effective amount of a composition comprising an isolated, substantially enantiomerically pure compound represented by:



or a pharmaceutically acceptable salt thereof.

20. A method of treating depression or anxious depression in a subject in need thereof, the method comprising administering to the subject in need thereof an effective amount of an isolated, substantially enantiomerically pure compound represented by:



5

or a pharmaceutically acceptable salt thereof.

10